Randomized controlled clinical trial on Roxithromycin Retard versus Roxithromycin in treatment of acute bacterial infections of respiratory system

ObjectiveIn order to evaluate the efficacy and safety of Roxithromycin Retard in the treatment of acute bacterial infections of respiratory system.[Methods]A randomized double-blind labeled controlled clinical trial was conducted for the treatment of 204 patients with respiratory tract infections. In the study,102 patients were enrolled in Roxithromycin Retard group while 102 patients were enrolled in Roxithromycin group. The dosage of Roxithromycin Retard was 300 mg,once daily orally while the dosage of Roxithromycin was 150 mg twice daily orally. The duration of treatment was 7～10 days in both groups.[Results]The results showed that the efficacy rates were 90.2% for Roxithromycin Retard group and 89.2% for Roxithromycin group, the bacterial clearance rates were 97.55% and 97.67%,respectively. The incidence of adverse reaction was 12.75% and 9.8%,respectively.[Conclusion]Roxithromycin Retard is effective and safe drug for acute bacterial infections of respiratory system.